{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:47:40Z","timestamp":1792478860983,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84065-0","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:44:08Z","timestamp":1735854248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Sun Hyung","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seok","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Kyu","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Moon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Bae","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84065_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil, N., van Zanten, S. V., Kahrilas, P., Dent, J. & Jones, R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101, 1900\u20131920 (2006). quiz 1943.","journal-title":"Am. J. Gastroenterol."},{"key":"84065_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5056\/jnm.2011.17.1.14","volume":"17","author":"HK Jung","year":"2011","unstructured":"Jung, H. K. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J. Neurogastroenterol Motil. 17, 14\u201327 (2011).","journal-title":"J. Neurogastroenterol Motil."},{"key":"84065_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5056\/jnm21077","volume":"27","author":"HK Jung","year":"2021","unstructured":"Jung, H. K. et al. 2020 Seoul Consensus on the diagnosis and management of gastroesophageal reflux disease. J. Neurogastroenterol Motil. 27, 453\u2013481 (2021).","journal-title":"J. Neurogastroenterol Motil."},{"key":"84065_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5056\/jnm21095","volume":"28","author":"SJ Kang","year":"2022","unstructured":"Kang, S. J., Jung, H. K., Tae, C. H., Kim, S. Y. & Lee, K. J. On-demand versus continuous maintenance treatment of gastroesophageal reflux disease with proton pump inhibitors: a systematic review and meta-analysis. J. Neurogastroenterol Motil. 28, 5\u201314 (2022).","journal-title":"J. Neurogastroenterol Motil."},{"key":"84065_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","volume":"123","author":"PF Haastrup","year":"2018","unstructured":"Haastrup, P. F., Thompson, W., S\u00f8ndergaard, J. & Jarb\u00f8l, D. E. Side effects of long-term proton pump inhibitor use: a review. Basic. Clin. Pharmacol. Toxicol. 123, 114\u2013121 (2018).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"84065_CR6","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/jcm13071970","volume":"13","author":"IO Sawaid","year":"2024","unstructured":"Sawaid, I. O. & Samson, A. O. Proton pump inhibitors and cancer risk: a comprehensive review of epidemiological and mechanistic evidence. J. Clin. Med. 13, 1970 (2024).","journal-title":"J. Clin. Med."},{"key":"84065_CR7","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3390\/cancers14133052","volume":"14","author":"TN Poly","year":"2022","unstructured":"Poly, T. N. et al. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel). 14, 3052 (2022).","journal-title":"Cancers (Basel)"},{"key":"84065_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/apt.15438","volume":"50","author":"S Han","year":"2019","unstructured":"Han, S. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 50, 751\u2013759 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"84065_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/apt.17728","volume":"58","author":"R Fass","year":"2023","unstructured":"Fass, R. et al. Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Aliment. Pharmacol. Ther. 58, 1016\u20131027 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"84065_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10388-018-00654-9","volume":"16","author":"Y Hoshikawa","year":"2019","unstructured":"Hoshikawa, Y. et al. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus 16, 201\u2013206 (2019).","journal-title":"Esophagus"},{"key":"84065_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins, H. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 41, 636\u2013648 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"84065_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/apt.14818","volume":"48","author":"J Sunwoo","year":"2018","unstructured":"Sunwoo, J. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 48, 206\u2013218 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"84065_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-2036.2004.02155.x","volume":"20","author":"HH Tsai","year":"2004","unstructured":"Tsai, H. H. et al. Esomeprazole 20\u00a0mg on-demand is more acceptable to patients than continuous lansoprazole 15\u00a0mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment. Pharmacol. Ther. 20, 657\u2013665 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"84065_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","volume":"49","author":"KJ Lee","year":"2019","unstructured":"Lee, K. J. et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment. Pharmacol. Ther. 49, 864\u2013872 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"84065_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11894-000-0013-0","volume":"2","author":"AB Thomson","year":"2000","unstructured":"Thomson, A. B. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr. Gastroenterol. Rep. 2, 482\u2013493 (2000).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"84065_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200847010-00001","volume":"47","author":"KM Fock","year":"2008","unstructured":"Fock, K. M., Ang, T. L., Bee, L. C. & Lee, E. J. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes. Clin. Pharmacokinet. 47, 1\u20136 (2008).","journal-title":"Clin. Pharmacokinet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84065-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T19:03:41Z","timestamp":1735931021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84065"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84065-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5062207\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by HK inno.N Corp., Seoul, Republic of Korea, whereby HK inno.N sponsored the study and provided the study drug. The sponsor had no role in the study design, study conduct, data analysis, and interpretation of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}